- Research article
- Open Access
Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment
BMC Complementary and Alternative Medicine volume 14, Article number: 153 (2014)
Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in treating lung cancer; a known anticancer Chinese herbal based formula.
In this study, A549 human lung carcinoma cell line and Lewis lung carcinoma xenograft mouse model were used. In addition, we utilized an in vitro co-culture system to simulate the tumor microenvironment in order to evaluate the molecular mechanisms of FLP treatment.
FLP treatment significantly inhibited tumor growth in the Lewis lung xenograft by 40 percent, compared to that of cyclophosphamide (CTX) of 62.02 percent. Moreover, combining FLP and CTX inhibited tumor growth by 83.23 percent. Upon evaluation, we found that FLP treatment reduced the concentration of serum pro-inflammatory cytokines IL-6, TNF-α, and IL-1β. In addition, we also found an improvement in E-cadherin expression and inhibition of N-cadherin and MMP9. We found similar findings in vitro when we co-cultured A549 cells with macrophages. FLP treatment inhibited A549 cell growth, invasion and metastasis, in part, through the regulation of NF-κB and altering the expression of E-cadherin, N-cadherin, MMP2 and MMP9.
FLP exerts anti-inflammatory properties in the tumor microenvironment, which may contribute to its anticancer effects. FLP treatment may be a promising therapy for inflammation associated lung cancer treatment alone, or in combination with conventional therapies and may prevent lung cancer metastasis.
Lung cancer is the most commonly diagnosed malignancy and the main cause of cancer-related deaths worldwide, with an estimated 15 percent 5-yr survival rate[1, 2]. While many advances in chemotherapy and radiotherapy have been made, overall patient survival rate has remained unchanged in recent years. During the early stages of lung cancer, surgery is effective; however, the five-year survival rate is approximately 25 percent, which is attributed mostly to remission and metastasis. Preventing reoccurrence and metastasis is an important step in improving the survival for lung cancer patients. Minimizing the severity of some side effects can improve the success of therapeutic methods and improve patient quality of life.
Traditional Chinese medicine has low toxicity accompanied with few side effects, and offers a promising therapy for lung cancer patients[4, 5]. Previous clinical and epidemiological studies demonstrated the efficacy of Traditional Chinese Medicine in treating lung cancer patients. Experimental studies show that traditional Chinese medicine has multiple roles and targets in the treatment of lung cancer patients[7, 8]; however, the mechanisms have yet to be elucidated.
Fei-Liu-Ping (FLP) ointment is an oral prescription medication that is used to treat lung cancer patients in China. FLP ointment has been shown to possess many anticancer properties, including improving the ability to stimulate dendritic cells, inhibiting VEGF and modulating MMP9 and TIMP-1 expression. The effects of FLP treatment on the tumor microenvironment have yet to be investigated.
The tumor microenvironment is an area of immense research; unlike normal cells, the microenvironment of cancer cells is hypoxic, acidic, hypertensive, with a greater number of growth factors secretion and proteolysis enzymes that promote proliferation and cell survival. In addition, the tumor microenvironment is in a chronic inflammatory state that has been shown to play a critical role in tumor growth, progression, and metastasis.
In the clinic, we have found that FLP ointment relieves the symptoms manifested in patients with lung cancer that may be associated with inflammation. We hypothesized that FLP ointment could alleviate inflammation within the microenvironment; thus, preventing progression and metastasis. In this study, we were able to show that FLP inhibits tumor growth in a Lewis lung cancer xenograft, and inhibit migration, invasion and metastasis in A549 lung cancer carcinoma cell lines under inflammatory conditions.
FLP ointment was supplied from Pharmaceutical preparation center of Guang’anmen Hospital, China Academy of Chinese Medical Sciences. (No.(98)JWY DF-1657) (Beijing, China). Cyclophosphamide (CTX) was supplied by Shanxi Powerdone Pharmaceutics Co. (Shanxi, China). Antibodies: NF-κB (p65), E-cadherin, N-cadherin, and MMP9, were purchased from Abcam (Cambridge, MA, USA). β-actin was purchased from Cell Signaling Technology (Danvers, MA, USA). ELISA kits for IL6, IL1β, and TNF-α were purchased from R&D systems (Minneapolis, MN, USA).
Preparation of FLP ointment
The herbs used in FLP ointment are the roots of Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao (Huang-Qi), Panax quinquefolium L. (Xi-Yang-Shen), Ophiopogon japonicas (Thunb.) Ker-Gawl. (Mai-Dong), Glehnia littoralis Fr. Schmidt ex Miq. (Bei-Sha-Shen), Agrimonia pilosa Ledeb. (Xian-He-Cao), Polygonum bistorta L. (Quan-Shen), Patrinia villosa (Thunb.) Juss. (Bai-Jiang-Cao), Panax notoginseng (Burk.) F.H. Chen (San-Qi), Fritillaria cirrhosa D. Don (Chuan-Bei-Mu), Glycyrrhiza uralensis Fisch. (Gan-Cao), Cordycrps sinensis(Berk.) Sacc. (Dong-Cong-Xia-Cao) and the fruits of Prunus persica (L.) Batsch (Tao-Ren) and Prunus armeniaca L. var ansu Maxim. (Xing-Ren). All those herbs were from Guang’anmen Hospital according to the original proportion, and decocted twice with 8-fold volume of distilled water for 1 hour. The decoction were collected, filtered, merged and concentrated to 2 g/mL (equivalent to crude herb materials), and stored at 4°C for oral using.
All mouse experiments were agreed to and regulated by the Ethical Committee of China Academy of Chinese Medical Sciences. Pathogen free male C57BL/6 mice were purchased from Vital River Company (Beijing, China) at 6-weeks of age and were maintained in a temperature- and humidity-controlled animal facility with a 12-h light/dark cycle. Animals were given free access to water and are monitored closely for any clinical signs of poor health throughout the study. All the animal experiments were conducted in accordance with the guidelines of the National Institutes of Health for the care and use of laboratory animals. After one-week acclimation, mice were randomly sorted into 5 treatment groups of 10 animals: Non-tumor-bearing (NT), Vehicle control (PBS) Fei-Liu-Ping ointment treated (FLP), cyclophosphamide treated (CTX), and FLP + CTX treated. Xenografts were performed under anesthesia by injecting 2 × 106 Lewis lung cancer cells in 0.1 ml volume into the right flank of the mouse. The following day, mice were treated according to group. FLP mice were treated orally with 100 mg/kg FLP by gavaging each day, for 21 days. CTX group mice were given three IP injections of CTX at 60 mg/kg, on day 2, 7, and 14 following tumor injection. FLP + CTX group mice were given a combination of CTX and FLP treatments described above. The vehicle control group received PBS gavaging each day, for 21 days. Mice were euthanized by CO2 asphyxiation on day 21 and tumor tissues were collected, measured and weighed. Serum from each mouse was also collected into 1.5 ml sterilized micro-tubes and kept on ice for 40 minutes, then centrifuged at 4°C at 3000 RPM for 15 minutes, and stored at -80°C for further analysis.
Tumor inhibition rate
Tumor inhibition rate was calculated as follows: Tumor inhibition rate = (1- average weight of tumors in treatment group/average weight of tumors in control group) × 100%.
Paraffin embedded tumor tissue was sectioned at 5 μm, onto glass microscope slides and subjected to immunohistochemical analysis. Briefly, tissue sections were deparaffinized in xylene and rehydrated in graded ethanol. Sections were then subjected to antigen retrieval and blocked for 1 hour in normal serum. Sections were incubated in primary antibody solution at the following dilutions, NF-κB, 1:50; N-cadherin, 1:100; E-cadherin, 1:200; MMP9, 1:200, overnight. This was followed by incubation in a horseradish peroxidase (HRP)-conjugated secondary antibody (Cell Signaling Technology) for 1 hour. Sections were visualized with 3, 3’diaminobenzidine (DAB) (Millipore, Billerica, MA, USA) and lightly counterstained with hematoxylin. Expression of positive cells was performed using image analysis software ImageProPlus 4.5 (Diagnostic Instruments, USA).
Western blot analysis
Western blot analysis of protein isolated from tumor tissue was performed as follows. Briefly, 100 mg tumor tissue from each sample was homogenized in 1 ml radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo scientific, Waltham, MA, USA). Protein concentration was calculated using standard bovine serum albumin (BSA) curve. Approximately 30 μg of protein was loaded and fractionated by SDS-PAGE and transferred to PVDF membrane and probed with the following primary antibodies at the indicated dilution. NF-κB (1:1000), E-cadherin (1:1000), N-cadherin (1:1000), MMP9 (1:500), and β-actin (1:5000) followed by a horseradish peroxidase (HRP)-conjugated secondary antibodies. Signal was visualized by adding ECL detection reagent (Amersham Life Science, Piscataway, NJ, USA).
A549 human adenoma cell line was obtained from cell resource center of the Institute of Basic Medical Sciences Chinese Academy of Medical Sciences. Cells were cultured in RPMI1640 with 10% FBS, 100U/ml penicillin and 100 mg/ml streptomycin at 37°C in humidified air with 5% CO2. THP-1 human monocyte cell line was obtained from cell resource center of the Institute of Basic Medical Sciences Chinese Academy of Medical Sciences and cultured in RPMI1640 with 10% FBS at 37°C in humidified air with 5% CO2.
To study the effects of Fei-Liu-Ping (FLP) ointment in vitro that closely resembles the serum bioavailability of FLP treatment in vivo, we utilized serum pharmacology previously described in[13–16]. Briefly, Wistar rats, a strain of albino laboratory rats that are often used to study safety and efficacy testing, were subjected to saline, FLP, or CTX treatment. Animals received either oral gavage of saline treatment, or FLP treatment at a low, medium or high dose (50, 100, 200 mg/kg, respectively), or IP injections of CTX (30 mg/kg) twice a day for three consecutive days. On the third day, serum was collected from the animals, filtered through a 0.2 μm cellulose acetate membrane. The serum collected was used for the treatments in all downstream in vitro assays and listed as follows; NRS (normal rat serum, saline treated), FLPL (FLP low dose), FLPM (FLP medium dose), FLPH (FLP high dose).
In-vitro system of inflammatory microenvironment
THP-1 cells were seeded on 6-well plates at 1 × 106 cells/well. The THP-1 monocyte cells were converted to macrophages using Phorbol 12-Myristate 13 acetate (PMA) purchased from Sigma Aldrich (Shanghai, China) at a final concentration of 320nM and incubated at 37°C with 5% CO2 for 48 hours to allow for maximal conversion of the THP-1 monocytes to THP-1 macrophages. All the experiments were performed in polystyrene with Transwell inserts with a pore size of 0.4 μm from BD Biosciences (San Diego, CA USA) using serum free medium. The co-culture experiments consisted of adding an insert containing confluent THP-1 macrophages to cultured A549 cells that are grown in the bottom compartment of the plate. The THP-1 macrophages were never in direct contact with the A549 cells. The cultures were exposed to either vehicle control or various FLP treatments. Cultured A549 without the addition of THP-1 macrophages was used as an experimental control. After 24 hours, the medium was recovered and stored at -80°C for further analysis.
ELISA detection of inflammatory cytokines
ELISA analysis was performed according to the manufacturers’ instructions and analyzed using a spectrometer reading at an absorbance of 450 nm with 570 nm used as the reference wavelength (Synogen4, Gene company Ltd).
Cell proliferation assay
A549 cells were incubated in 96-well plates in the presence of FLP or CTX treatments for 48 hours. MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide) purchased from Sigma-Aldrich (Shanghai, China) was added for 4 h at the final concentration of 0.5 mg/ml. Subsequently, the culture medium was removed and after dissolving the formazan crystals in DMSO, plates were read immediately at 570 nm using an absorbance plate reader (Bio- Rad, CA, USA). Cell survival was defined as the growth of treated cells compared with untreated cells.
Scratch wound assay
A549 cells were grown to confluence on a 24-well dish in serum-free medium. A single stripe (500 μM wide) was scraped on the cell-coated surface with a disposable plastic pipette tip. Cells were treated with FLP or CTX and incubated for 24 hours at 37°C with 5% CO2. Migration was analyzed using light microscopy with Image-Pro Plus Version 6.0.
Cell invasion was determined using Matrigel invasion chambers purchased from BD Biosciences (San Diego, CA, USA) and according to the manufacturers’ instructions. Briefly, 1 × 104 A549 cells were seeded into the upper chamber in serum free medium separated by a permeable membrane. The bottom chamber contained 10% serum in the presence or absence of FLP or CTX. Serum-free medium in the bottom chamber was used as a control. After 24 hours the cells in the membrane was fixed, stained and counted using light microscopy.
After pre-treatment with FLP or CTX, A549 cells were fixed for 20 minutes using 4% formaldehyde in PBS. The cells were blocked in 1% bovine serum albumin with 0.02% Triton X-100 for 1 hour and then incubated with primary antibodies, NF-κB (p65) (1:200), E-cadherin (1:200), N-cadherin (1:200), MMP9 (1:100), MMP2 (1:100), overnight at 4°C followed by a 1 hour incubation in Alex Fluor594 secondary antibody (1:400) and counterstained with DAPI. Molecular DevicesMetaXpress® Image Acquisition and Analysis Software were used for analysis of translocation of NF-κB p65, E-cadherin, N-cadherin, MMP2 and MMP9.
All data is presented as the mean ± standard deviation. The significance of the difference between groups was evaluated by one-way repeated-measures analysis of variance (ANOVA) and multiple comparisons with Prism 5.0 software. Student’s t-test for paired observation was used where appropriate. P < 0.05 were considered to be statistically significant.
FLP treatment inhibits tumor growth in Lewis lung cancer xenograft mice
To measure tumor growth inhibition caused by FLP ointment treatment Lewis lung cancer xenograft mice were treated with PBS, FLP ointment, CTX or a combination of FLP ointment and CTX. At the end of the study, the mice were euthanized and tumor tissues were measured and weighed. Figure 1A shows that FLP ointment inhibited the tumor growth compared with PBS vehicle group (p < 0.01). CTX could also significantly inhibit the tumor growth compared with PBS vehicle group (p < 0.01). FLP ointment combined with CTX was more effective in reducing the tumor growth compared with FLP ointment alone, or CTX alone. As shown in Figure 1B and C, FLP inhibition rate was 40 percent compared with PBS vehicle group; CTX inhibition rate was 64.02 percent compared with PBS vehicle group; the inhibition rate for FLP combined with CTX was 83.23 percent. From the above results, we found FLP ointment could inhibit the tumor growth of Lewis lung cancer, by itself or when combined with other conventional chemotherapeutic agent, CTX.
FLP treatment inhibits tumor-induced inflammatory cytokines expression in serum of Lewis lung cancer xenograft mice
FLP ointment was first prescribed in the clinic to lung cancer patients to relieve symptoms associated with inflammation, such as, cough, phlegm, and blood in the phlegm. Deregulation of inflammatory cytokines has been previously found to be associated with the above symptoms[17–20]. Serum collected from euthanized mice was analyzed for pro-inflammatory cytokines using ELISA. We found minimal detection of pro-inflammatory cytokines in the serum of the NT group (normal mice without tumor), whereas, tumor bearing mice had significantly elevated levels of TNF-α, IL-6 and IL-1β (Figure 1D, E and F). Interestingly, treatment with FLP decreased these cytokines to similar levels seen in normal mice without tumors. While a similar decrease in TNF-α and IL-1β was seen in the CTX treated mice, FLP treatment decreased IL-6 levels to a greater degree compared to that of the CTX treatment. Our results suggest that inflammation is induced by the tumor in Lewis lung cancer xenograft mice and FLP treatment could prevent tumor-associated inflammation.
FLP treatment reduces NF-κB expression in tumor tissue in vivo
NF-κB is activated by inflammatory stimuli and is found to be constitutively active in several cancers, as a result, it has long been suspected to be a critical inflammatory promoter facilitating the initiation and progression of cancer. NF-κB can induce pro-inflammatory cytokines, such as, IL-6 and TNF-α, and chemokine’s such as IL-8, adhesion molecules, MMPs, COX-2, and iNOS. We analyzed tumor tissue collected from the Lewis lung xenograft by immunohistochemistry (Figure 2A) and western blot (Figure 2B) for NF-κB p65 expression. We found that FLP treatment can reduce the expression of NF-κB compared to the PBS vehicle group. Interestingly, CTX treatment was found not to have any effect on NF-κB expression; however, when CTX is combined with FLP we found a significant decrease in NF-κB expression.
FLP treatment results in alterations of markers related to metastatic potential in vivo
Epithelial–Mesenchymal Transition (EMT) plays an important role in tumor invasion and metastasis. The major characteristic of EMT is the transformation from epithelial type cells to more motile, invasive and migratory mesenchymal type cells. In the process, epithelial cells lose cell-cell adhesion and cell polarity; In addition, decrease the expression of epithelial markers, such as, E-cadherin, and increase the expression of mesenchymal cell markers, such as, Vimentin, N-cadherin, alpha smooth muscle actin (α-SMA). In addition to EMT, deregulation of the extracellular matrix (ECM) and basement membrane by matrix metalloproteinase (MMPs), such as, MMP2, MMP9 is thought to play a key role in cancer cell invasion and metastasis[26, 27]. The presence of macrophages and TNF-α secretion can also increase the expression of MMPs[28, 29]. We analyzed the expression of E-cadherin, N-cadherin, and MMP9 in tumors collected from Lewis lung xenograft mice to measure the metastatic potential by immunohistochemistry (Figure 2A) and western blot (Figure 2B). As expected, we found altered expression of E-cadherin, N-cadherin, and MMP9 in PBS treated tumor bearing mice; Interestingly, FLP treatment, as well as, CTX treatment increased E-cadherin expression and decreased the expression of N-cadherin and MMP9, with a synergistic effect when FLP and CTX treatment was combined.
FLP treatment inhibits cell proliferation in vitro
In order to further evaluate the molecular mechanisms of FLP anticancer activities, we treated A549 lung carcinoma cells, with FLP or CTX treated rat derived serum (see cell culture methods). We first evaluated the effects of FLP treatment on cell proliferation in vitro. Using a MTT cell proliferation assay we found that FLP treatment could inhibit cell proliferation in A549 cells with the low dose achieving significant inhibition; however, not to the same level of inhibition seen with CTX treatment (Figure 3A).
FLP treatment inhibits cell invasion in an in vitro system of inflammatory microenvironment
Based on the earlier results from the xenograft studies, we found that inflammation may play a critical role in establishing the metastatic potential of lung tumors and that FLP may prevent migration and invasion; in part, by reducing pro-inflammatory cytokines and NF-κB. To directly test FLP efficacy in preventing invasion, possibly by modulating inflammation, we co-cultured A549 lung cancer cells with THP1-macrophages in a cell invasion assay. We found that a medium dose of FLP treatment could inhibit lung cancer invasion by 60% (Figure 4A, B). In addition, we found similar results in a scratch-wound migration assay (Figure 3B, C). We collected the supernatant from the co-culture medium at various times throughout the experiment to measure changes in pro-inflammatory cytokines. As expected, we found an increase in pro-inflammatory cytokines TNF-α, IL-6, and IL-1β when A549 cells are co-cultured with THP-1 macrophages. While, FLP treatment could reduce the level of TNF-α at 24 and 48 hours, the levels of IL-6 and IL-1β remained unchanged (Figure 4 C, D, and E). We concluded that FLP inhibition of invasion might be associated with changes in TNF-α.
FLP treatment inhibits NF-κB activity and nuclear translocation in vitro
Based on the FLP inhibition of TNF-α concentration described above and the proposed role of TNF-α in activating NF-κB, we examined NF-κB expression in A549 cells using immunofluorescence. We found that we could induce the nuclear translocation of NF-κB by 16.9 or 13.34 percent by co-culturing A549 cells with THP-1 macrophages or with the addition TNF-α, respectively; Interestingly, we found a 11.15 percent decrease in the nuclear translocation of NF-κB with FLP treatment, compared to that of known NF-κB p65 inhibitor, BAY11-7082 with 5.93 percent inhibition (Figure 5A, B).
FLP treatment reduces the expression of metastasis- associated proteins in vitro
NF-κB activity has been shown to regulate many downstream targets that may be associated with invasion and metastasis, including, transfer proteins, slug, snail, ZEB1, and E-cadherin, N-cadherin, and MMP9 as described above. Our xenograft study, implicated the influence of FLP treatment on several of the above markers, including, E-cadherin, N-cadherin and MMP9. We were able to support our in vivo findings by western blot showing that FLP treatment could increase the expression of E-cadherin and decrease the expression of N-cadherin and MMP9 (Figure 5D, E) in A549 cells cultured with THP-1 macrophages. In addition, we also found that FLP treatment could decrease the expression of snail, slug, ZEB1, Vimentin and MMP2, other proteins associated with metastasis (Figure 5C, D). We show similar results obtained by western blot with immunofluorescence, showing an increase in E-cadherin expression and decreased N-cadherin levels (Figure 6A, B), as well as, a decrease in MMP2 and MMP9 expression (Figure 7A, B).
Reducing tumor-associated inflammation and preventing reoccurrence and metastasis is an important therapeutic strategy for the management of lung cancer patients, and has posed a challenge for the medical community. Traditional Chinese Medicine offers great potential for enhancing current treatments for lung cancer, with minimum side effects. Although FLP ointment has been used to treat lung cancer and prevent lung cancer metastasis for many years in the clinic in China, the mechanisms are now being extensively investigated. In this study, we show that FLP treatment can inhibit tumor growth in a Lewis lung cancer xenograft study. FLP treatment inhibited tumor growth by approximately 40 percent; and when combined with chemotherapy drug CTX, inhibited tumor growth by 83.23 percent. Our results suggest that FLP treatment could improve the efficiency of chemotherapeutic drugs for the treatment of lung cancer.
Over the last decade, NF-κB has emerged as major pro-inflammatory mediator[30, 31], and has been implicated in playing a role in carcinogen-induced lung inflammation, tumor formation, tumor invasion and metastasis[32–35]. As a result, many efforts are being made to target the NF-κB pathway. The predominant mechanism of NF-κB activation involves phosphorylation, ubiquitination, and degradation of inhibitors of NF-κB (IκB), allowing NF-κB dimers to translocate to the nucleus and promote transcription of target genes[36–38].
While the correlation between cancer invasion and NF-κB activity has been determined the molecular mechanisms is only poorly understood. It is thought that NF-κB promotes tumor progression, mainly by protecting transformed cells from apoptosis. Some recent reports suggest that TNF-α is required for EMT and that NF-κB is essential for this process. We demonstrate that FLP treatment could inhibit both TNF-α and NF-κB activity in vivo and in vitro. In A549 FLP treated cells, we found a greater inhibition of NF-κB than that seen with treating A549 cells with a known NF-κB p65 inhibitor, BAY11-7082. The inhibition of NF-κB by FLP was also associated with changes in expression of important mediators during EMT and invasion. In both in vivo and in vitro models combining FLP with CTX rescued the altered expression of E-cadherin, N-cadherin and MMP9.
Our results show that FLP ointment is effective in regulating inflammation within the tumor microenvironment, through interactions with the NF-κB signaling pathway and may inhibit lung cancer invasion and metastasis. FLP treatment combined with conventional therapies may possibly be used to target other NF-κB activated cancers, such as, glioblastoma. The current evidence warrant further investigation, nonetheless, offers promising potential to play an integral part in the treatment and management of lung cancer patients.
Nuclear factor kappa light chain enhancer of activated B cells
Epithelial mesenchymal transition
Matrix metalloproteinase 2
Matrix metalloproteinase 9
Tumor necrosis factor alpha
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55 (1): 10-30. 10.3322/canjclin.55.1.10.
Tang JM, He QY, Guo RX, Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006, 51 (2): 181-191. 10.1016/j.lungcan.2005.10.003.
Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2001, 21 (6B): 4221-4229.
Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J: Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med. 2012, 12: 112-10.1186/1472-6882-12-112.
Guo H, Liu JX, Xu L, Madebo T, Baak JP: Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther. 2011, 10 (2): 127-137. 10.1177/1534735410387599.
Wan C, You S, Quan P, Song Y, Liu T, Lu J, Zheng P: Development and validation of the quality-of-life assessment system for lung cancer based on traditional Chinese medicine. Evid Based Complement Altern Med. 2012, 2012: 945910-
Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev. 2001, 27 (4): 235-246. 10.1053/ctrv.2001.0227.
Yang D, Tian G: Review of experimental study on treatment of lung cancer with traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi. 2009, 34 (18): 2405-2409.
Zhang P, Piao B, Sun G: Influence of feiliuping No. 2 on platelet surface glycoprotein expression in mid-late stage lung cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000, 20 (1): 31-33.
Zheng HG, Piao BK, Hua BJ: Effect of feiliuping ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010, 30 (12): 1288-1291.
Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013, 339 (6117): 286-291. 10.1126/science.1232227.
Candido J, Hagemann T: Cancer-related inflammation. J Clin Immunol. 2013, 33 (Suppl 1): S79-84.
Bochu W, Liancai Z, Qi C: Primary study on the application of serum pharmacology in Chinese traditional medicine. Colloids Surf B: Biointerfaces. 2005, 43 (3–4): 194-197.
Cao Y, Zhang D, Zheng G, Zhang J: Study on effect of drug concentration of "Bushen huayu jiedu fang" drug serum on drug-resistance lung cancer cells with serum pharmacology. Zhong Yao Cai. 2003, 26 (4): 263-265.
Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL: The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med. 1989, 18 (5): 680-687. 10.1016/0091-7435(89)90039-X.
Walther H, Meyer FP, Quednow B, Leuschner U, Kohler E, Horenburg I: Dosage monitoring through measurement of serum level–a task of clinical pharmacology. Int J Clin Pharmacol Biopharm. 1978, 16 (8): 387-390.
Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003, 97 (11): 2919-2925. 10.1002/cncr.11382.
Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS: A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004, 11 (5): 279-292. 10.1159/000079408.
Dantzer R: Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun. 2001, 15 (1): 7-24. 10.1006/brbi.2000.0613.
Rube CE, Wilfert F, Uthe D, Konig J, Liu L, Schuck A, Willich N, Remberger K, Rube C: Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004, 72 (2): 231-241. 10.1016/j.radonc.2004.05.004.
Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2 (4): 301-310. 10.1038/nrc780.
Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2 (10): 725-734. 10.1038/nri910.
Birchmeier W, Birchmeier C: Epithelial-mesenchymal transitions in development and tumor progression. EXS. 1995, 74: 1-15.
Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005, 17 (5): 548-558. 10.1016/j.ceb.2005.08.001.
Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006, 7 (2): 131-142. 10.1038/nrm1835.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25 (1): 9-34. 10.1007/s10555-006-7886-9.
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980, 284 (5751): 67-68. 10.1038/284067a0.
Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C: Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004, 25 (8): 1543-1549. 10.1093/carcin/bgh146.
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005, 175 (2): 1197-1205. 10.4049/jimmunol.175.2.1197.
Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004, 6 (3): 203-208. 10.1016/j.ccr.2004.09.003.
Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. in Cancer Res. 2009, 15 (2): 425-430.
Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS: Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A. 2007, 104 (47): 18514-18519. 10.1073/pnas.0705316104.
Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B: Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008, 6 (3): 364-371. 10.1158/1541-7786.MCR-07-0309.
Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009, 462 (7269): 104-107. 10.1038/nature08462.
Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010, 17 (1): 89-97. 10.1016/j.ccr.2009.12.008.
Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3 (1): 17-26. 10.1038/nrd1279.
Garg A, Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 2002, 16 (6): 1053-1068. 10.1038/sj.leu.2402482.
Zhang Y, Chen F: Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 2004, 64 (6): 1902-1905. 10.1158/0008-5472.CAN-03-3361.
Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol. 2002, 3 (3): 221-227. 10.1038/ni0302-221.
Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012, 72 (5): 1290-1300. 10.1158/0008-5472.CAN-11-3123.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/153/prepub
We thank all the researchers who were involved in this study and we thank Dr. Matthew R. Young for reviewing and revising this manuscript. We also thank Xin Qi and Yingxia Pei for technical assistance. We also thank Bingkui Piao for theory guidance of Chinese Medicine. This study was supported by the grant from National Natural Science Foundation of China. (No. 81273718; No. 81102587, No. 2012T50199, No. 20110490559) and from Ministry of Science and Technology of the People’s Republic of China. (No. 2010ZX09102-216).
The authors declare that they have no competing interests.
Conceived and designed the experiments: BH WL CC. Performed the experiments: WL CC LG GZ RL. Analyzed the data: WL CC SS. Contributed reagents/materials/analysis tools: WL CC LG. Wrote the paper: WL CC SS BH. All authors read and approved the final manuscript.
Weidong Li, Cihui Chen contributed equally to this work.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Li, W., Chen, C., Saud, S.M. et al. Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment. BMC Complement Altern Med 14, 153 (2014). https://doi.org/10.1186/1472-6882-14-153
- Lung cancer
- Fei-Liu-Ping ointment
- Nuclear factor kappa light chain enhancer of activated B cells
- Epithelial mesenchymal transition